BRIEF — Belite Bio Announces Multi — Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1

Oct 14 (Reuters) — Belite Bio, Inc: Belite Bio Announces Multi-market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1 Belite Bio - Submits Marketing Authorization Applications For Tinlarebant In Singapore, Uk, And Switzerland Belite Bio - U.s. Nda For Tinlarebant Accepted With Pdufa Target Action Date February 12, 2027 Source text:... Further company coverage: BLTE.O (((Reuters.Briefs@thomsonreuters.com;));)